Artificial Intelligence
Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
- New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers
- New integrated analyses from our tumour agnostic Rozlytrek® (entrectinib) clinical development programme
- Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating GavretoTM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer
- Impact of COVID-19 on cancer care: Roche live virtual panel discussions and Q&As featuring world leading healthcare experts
Basel, 17 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to results from the registrational phase I/II ARROW trial, investigating GavretoTM for the treatment of people with advanced, RET-mutant medullary thyroid cancer (MTC). Data from the phase III IPATential150 study in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN loss will also be shared.
Roche will also be hosting a live roundtable discussion that will focus on COVID-19 and the impact it may have on the outcomes for cancer patients. The discussion will focus on potential solutions and what lessons have been learned from the pandemic so far. Two additional sessions will look into pandemic-related lessons learned with regards to the integration of technology into patient management and the impact of digital tumour board solutions on multidisciplinary meetings.
“Our commitment to transforming the outcomes of people living with cancer remains steadfast, so we are proud to be presenting data at this year’s congress that advances the scientific understanding of multiple complex diseases,” said Levi Garraway, M.D., Ph.D. Roche’s Chief Medical Officer and Head of Global Product Development. “As a direct result of the pandemic, many countries are reporting a disruption to cancer care which could potentially result in the premature deaths of tens of thousands of cancer patients. Therefore, we must work together to ensure that we do not swap one health crisis for another: cancer patients simply cannot afford to wait.”
The pandemic has accelerated the need for collaboration among all stakeholders involved in cancer care to address key gaps and challenges that require urgent action by governments and policy makers. To discuss these issues and call for a course correction for all cancer care services, a live virtual panel discussion and Q&A featuring leading experts from medical societies, academia and the patient group community, will take place on Tuesday 22 September 2020, 15:00 CEST. Join this event on Roche’s LinkedIn page here. Two additional sessions will look into related topics in the context of treatment decision making. In the first session, insights will be shared by Italian experts on how the pandemic has affected cancer care and how digital solutions helped them to continue shared decision making remotely. Sign up here for the session on Saturday, 19 September, 16:00-16:30 CEST. The second talk illustrates challenges faced by multidisciplinary teams when convening tumour boards and their real-world experience with a digital tumour board solution in the pandemic. Sign up here for the session on Saturday, 19 September, 16:30-17:00 CEST.
Roche highlights featured at ESMO Virtual Congress 2020
Breast cancer portfolio
At ESMO, results from recent studies across the Tecentriq TNBC programme (both early and metastatic TNBC) will be presented, including final OS analysis from the phase III IMpassion130 study (Tecentriq in combination with nab-paclitaxel [Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound)] in mTNBC)], results from the IMpassion031 study (Tecentriq in combination with nab-paclitaxel [Abraxane, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide] in the early TNBC setting), and results from the phase III IMpassion131 study (Tecentriq in combination with paclitaxel in mTNBC).
In HER2-positive breast cancer, results will highlight our focus on improving patients’ experience of cancer treatment, looking beyond efficacy outcomes and focusing on more flexible treatment solutions. Data from the phase II PHranceSCa study show the majority of patients prefer treatment with Phesgo™, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), compared to standard intravenous formulations. Phesgo was recently approved by the U.S. Food and Drug Administration, about four months earlier than anticipated, for the treatment of early and metastatic HER2-positive breast cancer. Based on the decision of the treating physician and the preference of the patient, it can be administered by a healthcare professional in a treatment centre or in a patient’s home.
Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation. GDC-0077 is our next generation investigational PI3Kα-selective inhibitor and mutant PI3Kα degrader designed to inhibit the growth of tumour cells that have mutations in the PIK3CA gene. We will present PI3K pathway biomarker and clinical response data from a phase I/Ib study of GDC-0077 and announce the design of an ongoing phase III study evaluating GDC-0077 in HR-positive, HER2-negative advanced breast cancer. In addition, results will be shared from phase III IPATunity130 cohort B assessing ipatasertib in combination with paclitaxel in patients with PIK3CA/AKT1/PTEN-altered HR-positive advanced breast cancer.
Tecentriq in lung cancer
Results from an exploratory analysis of characterisation of long-term survivors (LTS), defined in the study as people who survived for longer than 18 months following randomisation, in the IMpower133 trial will be presented in a mini-oral session. The study previously showed that Tecentriq in combination with chemotherapy helped people with extensive-stage small cell lung cancer (ES-SCLC) live significantly longer compared with chemotherapy alone. SCLC is distinguished from other lung cancer subtypes due to its aggressive nature, rapid growth and early development of metastatic disease.
In addition, four-year survival data from the phase II POPLAR and phase III OAK studies, investigating Tecentriq vs docetaxel (chemotherapy) in patients with advanced pre-treated non-small cell lung cancer (NSCLC) will be presented.
Tumour-agnostic data
Two sets of CNS efficacy data from integrated analyses of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented, including a poster presentation evaluating the efficacy of Rozlytrek in patients with NTRK or ROS1 fusion-positive NSCLC, who have CNS metastases at baseline; and an oral presentation evaluating the intracranial efficacy of Rozlytrek in patients with NTRK fusion-positive solid tumours with baseline CNS metastasis. In addition, an updated integrated analysis of the phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials, investigating the efficacy and safety of Rozlytrek in locally advanced/metastatic ROS1-positive NSCLC, which evaluated a larger dataset with longer follow-up (15.8 months) will be presented.
Gavreto in RET-mutant medullary thyroid cancer
At ESMO, Blueprint Medicines will present results from the registrational phase I/II ARROW trial, investigating Gavreto for the treatment of people with advanced, RET-mutant medullary thyroid cancer. Gavreto is being jointly commercialised by Genentech, a wholly owned member of the Roche Group, and Blueprint Medicines in the U.S. and will be commercialised by Roche outside of the U.S., excluding Greater China (encompasses Mainland China, Hong Kong, Macau and Taiwan). Blueprint Medicines and Gavreto are trademarks of Blueprint Medicines Corporation.
Subcutaneous formulation of atezolizumab (Tecentriq)
First data from the phase Ib dose-finding study (Part 1 of IMscin001) of subcutaneous atezolizumab (Tecentriq) in patients with locally advanced or metastatic NSCLC will also be presented. The subcutaneous formulation of atezolizumab (Tecentriq) is being developed to potentially allow faster administration via an injection under the skin, compared to the original intravenous (IV) formulation, thereby significantly reducing a patient’s time spent receiving treatment. Based on previous studies of other monoclonal antibodies, subcutaneous is generally a preferred route of administration by patients, physicians, healthcare providers and can be associated with hospital time- and cost-savings.
PHC symposium
In light of ESMO’s 2020 motto, “bringing innovation to cancer patients”, Roche is hosting a symposium that explores what it takes to put personalised healthcare at the heart of clinical practice. Leading experts will discuss recent innovations in the field of personalised healthcare within oncology like the use of blood based molecular testing. Furthermore, the panelists will also discuss how to accelerate the adoption personalised oncology in healthcare systems. The symposium is tailored for healthcare professionals and includes a virtual live Q&A with the faculty on Friday, 18 September, 17:00-17:30 CEST.
Follow Roche on Twitter via @Roche and keep up to date with ESMO news and updates by using the hashtag #ESMO20.
Overview of key presentations featuring Roche medicines at ESMO 2020
Medicine | Abstract title | Abstract number |
Triple-negative breast cancer | ||
Tecentriq® (atezolizumab) | Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC) | LBA15 (Oral), Saturday, 19 September, (Channel 1) 16:20-16:32 CEST |
Tecentriq | IMpassion031: results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC) | LBA11 (Oral), Sunday, 20 September, (Channel 3) 12:30-12:42 CEST |
Tecentriq | IMpassion130: final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer | LBA16 (Oral), Saturday, 19 September, (Channel 1) 16:32-16:44 CEST |
HER2-positive breast cancer | ||
Phesgo™ (pertuzumab- trastuzumab) | Patient preference for the pertuzumab–trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study | Presentation #165MO (Oral), Friday, 18 September (On-demand) |
Perjeta® (pertuzumab) and Herceptin® (trastuzumab) | Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC) | Presentation #228P (Poster), Thursday, 17 September (On-demand) |
HR-positive breast cancer | ||
GDC-0077 | Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC) | Presentation #355TiP (Poster), Thursday, 17 September (On-demand) |
GDC-0077 | PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC) | Presentation #336P (Poster), Thursday, 17 September (On-demand) |
Ipatasertib | Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase 3 trial | Presentation #283MO (Oral), Friday, 18 September (On-demand) |
Lung cancer | ||
Alecensa® (alectinib) | Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from Blood First Assay Screening Trial (BFAST) and comparison with real-world data (RWD) | Presentation #1307P (Poster), Thursday, 17 September (On-demand) |
Alecensa | Blood First Assay Screening Trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses | Presentation #1301P (Poster), Thursday, 17 September (On-demand) |
Tecentriq | IMpower133: characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer | Presentation #1781MO (Mini-oral), Friday, 18 September (On-demand) |
Tecentriq | 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC |
Presentation #1271P (Poster), Thursday, 17 September (On-demand) |
Tecentriq | IMscin001: phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) |
Presentation #1270P (Poster), Thursday, 17 September (On-demand) |
Flatiron Health data in lung cancer | ||
Real world data | Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study | Presentation #519P (Poster), Thursday, 17 September (On-demand) |
Real world data | Pan-cancer analysis of homologous recombination (HR)-associated alterations (alts) and genome-wide loss of heterozygosity (gLOH) | Presentation #85MO (Oral), Friday, 18 September (On-demand) |
Solid tumours | ||
Rozlytrek® (entrectinib) | Efficacy and safety of entrectinib in locally advanced /metastatic ROS1 fusion-positive NSCLC: an updated integrated analysis | Presentation #1287P (Poster), Thursday, 17 September (On-demand) |
Rozlytrek | Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline | Presentation #1288P (Poster), Thursday, 17 September (On-demand) |
Rozlytrek | Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases | Presentation #364O (Oral), Sunday, 20 September, 13:38-13:50 CEST |
GavretoTM (pralsetinib) | Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+MTC) (Blueprint) | Presentation #1913O (Oral) Sunday, 20 September, 15:21-15:33 CEST |
Genitourinary cancers | ||
Tecentriq | Patient-reported outcomes (PROs) from IMvigor130: a global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) | Presentation #698O (Oral), Saturday, 19 September, 17:16-17:28 CEST |
Perjeta and Herceptin | End-of-study analysis from JACOB: a phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC) | Presentation #1423MO (Oral), Friday, 18 September (On-demand) |
Ipatasertib | IPATential150: phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) | LBA4 (Presidential symposium II), Sunday, 20 September, (Channel 1) 19:02-19:14 CEST |
Liver cancer | ||
Tecentriq and Avastin® (bevacizumab) | Efficacy of atezolizumab + bevacizumab After Disease Progression With Atezo Monotherapy in Patients With Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC) | Presentation #986P (Poster), Thursday, 17 September (On-demand) |
Tecentriq and Avastin | IMbrave150: management of adverse events of special interest (AESIs) for atezolizumab and bevacizumab in unresectable HCC | Presentation #1008P (Poster), Thursday, 17 September (On-demand) |
Gynecological cancer | ||
Tecentriq | Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) | LBA31 (Oral) Monday, 21 September, (Channel 3) 16:20-16:32 CEST |
About Roche in Oncology
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast.
The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa® (alectinib); Avastin® (bevacizumab); Cotellic® (cobimetinib); Erivedge® (vismodegib); GavretoTM (pralsetinib); Gazyva®/Gazyvaro® (obinutuzumab); Herceptin® (trastuzumab); Kadcyla® (trastuzumab emtansine); MabThera®/Rituxan® (rituximab); Perjeta® (pertuzumab); Polivy® (polatuzumab vedotin-piiq); Tarceva® (erlotinib); Rozlytrek® (entrectinib); Tecentriq® (atezolizumab); Venclexta®/Venclyxto® (venetoclax); Xeloda® (capecitabine); Zelboraf® (vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit www.roche.com.
About Roche in Personalised Healthcare
For more than 20 years, Roche has helped lay the scientific groundwork for personalised healthcare with treatments that target the underlying biology of cancer and other diseases. Now, with profound changes in data and technology transforming how medicines are discovered, developed and delivered to patients, we are uniquely positioned to extend this approach across all of healthcare. With our ability to integrate research and development, personalised diagnosis, disease monitoring and treatment access, we are advancing personalised healthcare for every aspect of the patient experience.
Our strategy is rooted in groundbreaking science that can accelerate drug discovery and development. We are also leveraging technologies such as real-world datasets, artificial intelligence, genomic profiling and digital health across our therapeutic portfolio, with an initial emphasis on oncology, neurology, ophthalmology and diagnostics. Through collaborations with academic institutions, industry partners, patients, physicians and regulatory agencies, our goal is to dramatically improve the performance of the entire healthcare ecosystem and the lives of every patient.
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]
Dr. Nicolas Dunant Phone: +41 61 687 05 17 |
Patrick Barth Phone: +41 61 688 44 86 |
Daniel Grotzky Phone: +41 61 688 31 10 |
Karsten Kleine Phone: +41 61 682 28 31 |
Nina Mählitz Phone: +41 79 327 54 74 |
Nathalie Meetz Phone: +41 61 687 43 05 |
Barbara von Schnurbein Phone: +41 61 687 89 67 |
Attachment
Artificial Intelligence
NEW PRODUCT, NEW TECHNOLOGY, NEW STRATEGY: NETA AUTO POISED TO SHOCK 2024 BEIJING INTERNATIONAL AUTOMOTIVE EXHIBITION
BEIJING, April 18, 2024 /PRNewswire/ — 2024 Beijing International Automotive Exhibition, the largest international auto show this year, is about to open, attracting global attention. As the leading EV brand in China, NETA has officially announced its participation in this exhibition. From 25th April to 4th May, visitors can experience its latest technologies and brand-new product lineup at booth E405 in CIEC (Shunyi Hall, Beijing).
Adhering to the brand value of “Tech for All” and brand mission of “Touchable Smart EV”, NETA Auto is dedicated to provide high-quality smart EVs and advance technology to global users. At the upcoming exhibition, NETA Auto will introduce a brand-new lineup of products. Not only its existing models, NETA X and NETA S, but also unveil the new model, NETA L.
NETA L will debut in both REEV and EV version. It will be delivered to its first Chinese customer at Beijing auto show and will be launched in over 20 countries worldwide during the second half of this year. NETA L will offer an REEV version with an extraordinary combined range of 1070 kilometers. Additionally, NETA L’s most striking feature is its integration with NETA’s all new AI flagship technology – NETA GPT, which will offer global users with a smarter NETA assistant and will redefine the experience of intelligent cockpits.
At this exhibition, NETA Auto will not only showcase its innovative strength and brand-new product lineup of smart EVs, but also seize opportunities to launch series of overseas activities. This move aims to further drive NETA’s global expansion and bring high-quality smart EVs to global customers in vast markets, such as Southeast Asia, the Middle East, and Latin America.
About NETA Auto
NETA Auto, a brand of Hozon New Energy Automobile Co., Ltd., is a leading innovator in the smart EV industry. With a focus on “Tech for All” and “Touchable Smart EV”, NETA develops high-quality EV and cutting-edge technologies. Its lineup includes popular models such as NETA AYA, NETA X, NETA L, NETA GT, and NETA S.
NETA dedicate to bring smart EV to global mass consumer market, introducing new model each year and covering the A0-B segments. NETA has also developed the “Shanhai Platform,” an intelligent and safe car platform, and HOZI Technology, which is committed to develop advanced technologies to meet user demands continuously.
Photo – https://mma.prnewswire.com/media/2390906/NETA_L.jpg
View original content:https://www.prnewswire.co.uk/news-releases/new-product-new-technology-new-strategy-neta-auto-poised-to-shock-2024-beijing-international-automotive-exhibition-302120989.html
Artificial Intelligence
Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions
Using patient personality traits to pioneer a new era in clinical research.
MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ — Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a significant investment milestone. Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d’Investissement) and WE (Wallonie Entreprendre) have committed strategic investments to drive Cognivia’s mission to “quantify the power of the mind” to optimize and accelerate drug development programs. This infusion of capital will allow Cognivia to deploy its predictive clinical trial solutions that decode the relationship between patient traits and behaviors, thus expediting the development of innovative treatments for patients globally.
Cognivia’s solutions target critical areas that have historically posed significant challenges to drug development, such as the placebo response and medication adherence in clinical trials. Unlike any other, Cognivia is pioneering a quantitative understanding of patients as individuals and integrating these insights into the analysis of clinical trial data and/or optimization of patient engagement strategies. For instance, Placebell™ utilizes predictive algorithms to mitigate the negative impact of the placebo response, enhancing the study power of clinical trials, resulting in increased success rates and reduced clinical trial timelines and costs. Compl-AI predicts the risk of non-compliance and dropout of a patient at screening and during your clinical trial, helping to strengthen and personalize patient engagement strategies.
The capital raised will catalyze Cognivia’s endeavors to introduce its groundbreaking solutions to the market and cement a robust presence in the United States. Through the expansion of its team and the establishment of a subsidiary in the US, Cognivia seeks to foster enhanced commercial and R&D collaborations. In the near future, we plan to fortify our network through strategic alliances, bolstering our advisory board with new members, and building out teams in both the US and EU. This strategic maneuver is in perfect alignment with Cognivia’s steadfast dedication to becoming a leading partner for pharmaceutical and biotechnology companies, empowering them to develop efficacious treatments to address unmet patient needs.
In this latest funding round, Cognivia proudly welcomes the support of three esteemed investors: Vesalius Biocapital IV, a Luxembourg-based venture-capital fund focusing on best-in-class investments in HealthTech and biopharma; SFPIM, the Belgian Sovereign Wealth Fund, providing strategic guidance and financial support for Belgian companies; and WE, contributing to Wallonia’s economic development through financing and support across various sectors.
“We are thrilled to announce Cognivia as the inaugural investment of our fund IV, which focuses on HealthTech and biopharma companies at the forefront of innovation transforming healthcare. We eagerly anticipate partnering with them throughout their commercialization and growth stages.” says Olivier Houben, Partner at Vesalius Biocapital.
“Cognivia’s strategic alliances with Vesalius Biocapital IV, SFPIM and WE signify a pivotal moment in our quest to transform the industry through a unique blend of decades-long industry experience and advanced AI,” remarked Dominique Demolle, CEO/Co-founder of Cognivia. “With this investment and the welcomed addition of new members to our operational team and Company Board and Strategic Advisory Committee, to be announced soon, we are poised to accelerate our efforts in delivering groundbreaking approaches that empower clinicians, researchers and industries to make informed, data-driven decisions, ultimately enhancing outcomes for patients and stakeholders worldwide.”
About Cognivia
Cognivia is the first and only company to combine quantification of patient psychology with artificial intelligence (AI)/machine learning (ML) to improve measurement of therapeutic efficacy in clinical trials – and beyond. Cognivia technologies predict patient behavior and treatment response in clinical trials using predictive ML powered algorithms based on a quantitative understanding of patient psychological traits, expectations and beliefs collected via our own and specific questionnaires developed toward that objective. Cognivia aims at harnessing “the power of the mind” and quantifying this unique phenomenon to improve clinical trial success rates, de-risk drug development and ultimately improve healthcare.
For further details on Cognivia and its groundbreaking AI solutions, please visit cognivia.com or follow @cognivia on LinkedIn.
For media inquiries, please contact: Stephanie AlvarezMarketing Director at [email protected]
Logo – https://mma.prnewswire.com/media/2082754/Cognivia_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cognivia-secures-strategic-15-5m-funding-to-empower-drug-development-with-ai-ml-solutions-302120166.html
Artificial Intelligence
Sapiens Launches IntegrateAI, the Second Release in its DecisionAI Portfolio
IntegrateAI addresses growing market demand for a single, integrated business application that leverages machine learning models in decision management
ROCHELLE PARK, N.J., April 18, 2024 /PRNewswire/ — Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced the launch of IntegrateAI, the newest capability from Sapiens Decision, integrating machine learning models into the business-friendly decision model workbench.
Sapiens Decision users can integrate machine learning models as another component of their decision model diagram, combining declarative and probabilistic constructs into one consistent and explainable model. Enabling non-technical users to incorporate the machine learning models from data science teams into a single decision model dramatically reduces business and technical complexities, driving greater operational control and efficiency.
IntegrateAI follows Sapiens Decision’s recent ModelAI release, which brought a Generative AI (GenAI) copilot to decision modelers with integration to Microsoft Azure’s OpenAI Service. The two releases fulfill the initial AI strategy and roadmap of Sapiens Decision to increase the access, speed, and efficacy of decision automation for business users. Sapiens Decision is planning additional AI based products to support the full lifecycle of the decision modeling process, including ExtractAI (for extracting decision logic from legacy code) and OptimizeAI (to optimize business decisions for specific outcomes).
“Sapiens Decision IntegrateAI enables organizations to implement decision automation with greater transparency, explainability, and efficiency by enabling business users to integrate machine learning models within decision models,” said Ilan Buganim, Sapiens CTIO. “Combined with Sapiens Decision’s copilot ModelAI, which leverages GenAI to automatically convert natural language to decision models, enterprises can now turbocharge their application of decision automation for greater business outcomes.”
Sapiens Decision provides end-to-end decision management capabilities from decision logic extraction from legacy code to decision modeling with no code tools, and deployment through Decision-as-a-Service. Sapiens Decision offers a technology-independent solution to fit any architecture, allowing organizations to reuse their existing infrastructure and governance models.
Sapiens will be showcasing IntegrateAI at Insurance Innovators USA, Nashville, TN on April 22-23, 2024.
About Sapiens
Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. With more than 40 years of industry expertise, Sapiens’ cloud-based SaaS insurance platform offers pre-integrated, low-code capabilities across core, data, and digital domains to accelerate our customers’ digital transformation. Serving over 600 customers in more than 30 countries, Sapiens offers insurers across property and casualty, workers’ compensation, and life insurance markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information visit https://sapiens.com or follow us on LinkedIn.
Investor and Media Contact Yaffa Cohen-Ifrah Sapiens Chief Marketing Officer and Head of Investor Relations Email: [email protected]
Forward Looking Statements
Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; the global macroeconomic environment, including headwinds caused by inflation, relatively high interest rates, potentially unfavorable currency exchange rate movements, and uncertain economic conditions, and their impact on our revenues, profitability and cash flows; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the coronavirus epidemic, and fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.
While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, to be filed in the near future, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.
Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/sapiens-launches-integrateai-the-second-release-in-its-decisionai-portfolio-302120940.html
-
Artificial Intelligence6 days ago
In-Depth Analysis of Germany and France Data Center Markets: Germany Poised to Contribute Over $12.24 Billion Opportunities in the Next 6 Years – Arizton
-
Uncategorized6 days ago
Arm CEO Rene Haas will be delivering a Partner’s Event Speech at COMPUTEX 2024
-
Uncategorized6 days ago
BJEI: A New Record of High Performance in 2023 and a New Pattern of Diversified and Coordinated Development
-
Uncategorized6 days ago
Integrity Food Marketing Joins Forces with CA Ferolie to Expand East Coast Reach from Maine to Florida
-
Uncategorized6 days ago
Dimethyl Carbonate Market worth $1.9 billion by 2028 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence6 days ago
CogX Festival Set to Debut in Los Angeles at Century Plaza on May 7th, 2024
-
Artificial Intelligence6 days ago
aelf Leads the Fusion of AI and Blockchain to Shape the Future of Technology
-
Artificial Intelligence6 days ago
Xinhua Silk Road: Zoomlion Access pursues high-quality development with aerial work machinery sector innovation